GLP-1R agonists may significantly improve clinical symptoms in COPD patients, alleviate airflow limitation, influence airway damage, fibrosis and remodelling, shorten hospital stays, reduce patients’ financial burden, reduce the risk of COPD-related complications, improve patients’ long-term prognosis, and may be a novel target for the prevention and treatment of COPD [100]. This evidence concerns the gene GLP1R and chronic obstructive pulmonary disease.